High-Throughput Screening Reveals Potential Inhibitors Targeting Trimethoprim-Resistant DfrA1 Protein in Klebsiella pneumoniae and Escherichia coli

Hasnat, S.; Rahman, S.; Alam, M. B.; Suin, F. M.; Yeasmin, F.; Suha, T.; Supty, N. T.; Sabila, S.; Chowdhury, A.; Shahinuzzaman, A. D. A.; Mahbub, M. M.; Hoque, M. N.; Islam, T.

doi:10.1101/2024.11.18.624070

bioRxiv · 10.1101/2024.11.18.624070

High-Throughput Screening Reveals Potential Inhibitors Targeting Trimethoprim-Resistant DfrA1 Protein in Klebsiella pneumoniae and Escherichia coli

Hasnat, S.·Rahman, S.·Alam, M. B.·Suin, F. M.·Yeasmin, F.·Suha, T.·Supty, N. T.·Sabila, S.·Chowdhury, A.·Shahinuzzaman, A. D. A.·Mahbub, M. M.·Hoque, M. N.·Islam, T.

View original source ↗Export metadata ↓

Abstract

The DfrA1 protein provides trimethoprim resistance in bacteria, especially Klebsiella pneumoniae and Escherichia coli, by modifying dihydrofolate reductase, which reduces the binding efficacy of the antibiotic. Thus, this study aimed to identify inhibitors of the trimethoprim-resistant DfrA1 protein through high-throughput computational screening of 3,601 newly synthesized chemical compounds sourced from the ChemDiv database. We conducted high-throughput computational optimization and screening of a library containing 3,601 compounds against the DfrA1 protein from K. pneumoniae and E. coli to identify potential drug candidates (DCs). Through this extensive approach, we identified six promising DCs, labeled DC1 to DC6, as potential inhibitors of DfrA1. Each DC demonstrated strong initial binding affinity and favorable chemical interactions with the DfrA1 binding sites when compared to the effective drug Iclaprim (effective antibiotic against DfrA1), used as a control. To validate these findings, we further investigated the molecular mechanisms of inhibition, focusing on the thermodynamic properties of the promising DCs. Furthermore, molecular dynamics simulation (MDS) validated the inhibitory efficacy of these six DCs against the DfrA1 protein. Our results showed that DC4 (an organoflourinated compound) and DC6 (a benzimidazol compound) showed superior efficacy against the DfrA1 protein than the control drug, particularly regarding stability, solvent-accessible surface area, solvent exposure, polarity, and binding site interactions, which influence their residence time and efficacy. Overall, findings of this study suggest that DC4 and DC6 have the potential to act as inhibitors against the DfrA1, offering promising prospects for the treatment and management of infections caused by trimethoprim-resistant K. pneumoniae and E. coli in both humans and animals.

Explore related subjects

bioinformatics Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Hasnat, S., Rahman, S., Alam, M. B., Suin, F. M., Yeasmin, F., Suha, T., Supty, N. T., Sabila, S., Chowdhury, A., Shahinuzzaman, A. D. A., Mahbub, M. M., Hoque, M. N., Islam, T.. 2024-11-18. High-Throughput Screening Reveals Potential Inhibitors Targeting Trimethoprim-Resistant DfrA1 Protein in Klebsiella pneumoniae and Escherichia coli. https://doi.org/10.1101/2024.11.18.624070

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Targeted finetuning enables co-folding models to learn ligand-induced protein conformational states

Advances in protein structure prediction have enabled all-atom protein-ligand co-folding models that predict bound conformations directly from sequence and small-molecule structure. However, these models often fail to generalize to novel binding sites or alternative protein conformational states, limiting their utility for chemical biology and drug discovery. Here we show this limitation reflects training data bias rather than architectural constraints and can be overcome through targeted finetuning. Using ten previously unseen X-ray structures of Werner (WRN) helicase from a drug discovery program, we finetune Boltz-1 to learn both an allosteric binding site and a large conformational change locking the enzyme in an inactive state, while preserving accuracy on the ATP-bound state. The finetuned model generalizes to different chemical series and transfers the conformational logic across RecQ-family helicases in a binding-site sequence-dependent manner. This approach provides a blueprint for adapting foundation models as new structural and mechanistic data emerge, enabling co-folding networks to capture ligand-induced conformational switches and binding poses absent from their training data but central to biological regulation and therapeutic intervention.

bioinformatics↗

bioRxiv2026

Benchmarking single-cell foundation models for aging biology

Single cell foundation models (scFMs) provide representations of cellular states, but their utility across biological questions in aging research remains unclear. We established a benchmark of cellular representations for aging research, evaluating ten general-purpose scFMs, three aging-specific models and conventional methods across five biological questions using more than 2.5 million single cell transcriptomes. Using frozen pretrained representations, Geneformer performed best among scFMs for chronological age prediction and age pseudotime concordance, although 2,000 highly variable genes achieved higher mean performance. Several scFMs captured positive molecular age shifts across three disease contexts, consistent with reported aging-associated changes. SCimilarity performed well for rare cellular state identification across out-of-distribution datasets, exceeding aging specific models and conventional baselines. At the gene level, scGPT showed the highest recovery of reference TF target interactions, including aging-related regulatory hubs. Overall, scFMs supported diverse aging analyses, but performance depended on the biological question, highlighting their utility for rare cellular state identification and regulatory analysis.

bioinformatics↗

bioRxiv2026

CryoMV: Structure-Prior-Guided Modeling and Real-Particle Validation of Continuous Conformational Transitions in Cryo-EM

Continuous protein conformations are essential for understanding fundamental biological processes and supporting drug discovery. Although cryo-EM can resolve individual states at high resolution, recovering continuous heterogeneity from 2D particle images remains challenging. High noise, motion blur, and limited structural priors make it difficult to accurately generate and validate high-resolution continuous conformations using raw particle data. Here, we introduce cryoMV, a framework that integrates structure-prior-guided modeling with real-particle validation for continuous conformational transitions. CryoMV uses reference density maps to establish structural anchors and motion priors, models candidate transition paths between selected conformations, and transfers the learned representation to raw 2D cryo-EM particle images. Each candidate conformation is subsequently evaluated using the estimated particle poses and contrast transfer functions. Supported conformations are reconstructed through raw particle back-projection and assessed using canonical half-maps and Fourier shell correlation. On EMPIAR-10516 and EMPIAR-10345, cryoMV achieves excellent performance in terms of robustness, verifiability, and reconstruction resolution. By incorporating structure-prior modeling and evidence from the raw particles, cryoMV offers an explicit mechanism for assessing whether generated conformations are supported by experimental data and provides a practical approach to reducing model-induced artifacts in continuous cryo-EM heterogeneity analysis.

bioinformatics↗